This clinical research study is for adults 18 to 75 years old who have been diagnosed with active Systemic Lupus Erythematosus (SLE). The study will evaluate the safety and effectiveness of an investigational oral medication, deucravacitinib, in reducing symptoms of lupus.
What to Expect
Participants will be randomly assigned to receive either the investigational study medication or a placebo. Neither participants nor study staff will know which treatment is assigned during the study.
All study-related care is provided at no cost. Participants may receive up to $200 per visit for time and travel.
Eligible participants may also qualify for reimbursement of additional expenses, including lodging, meals, and caregiver support, depending on location and need.
Trial Requirements
- Adults 18–75 years old
- Diagnosed with Systemic Lupus Erythematosus (SLE)
- Must have symptoms such as joint involvement or rash
- Positive antibody test (ANA, anti-dsDNA, or anti-Smith)
- Receiving background SLE treatment
- Willing to follow study visit schedule
Urgently Recruiting
Trial Details
This study aims to assess the safety, tolerability, and potential benefit of deucravacitinib, an investigational oral medication. This medication is already approved for plaque psoriasis, and now it is being evaluated in a Phase 3 lupus study.
Participants may be enrolled for up to 38 months, which includes:
A screening period
A 12-month double-blind treatment period (you have a 60% chance of receiving the active drug)
An optional 2-year open-label extension, where all participants receive the study drug
A follow-up health check
Participants will undergo regular health assessments, including lab tests and symptom monitoring, to evaluate the effects of the study medication.
